BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

678 related articles for article (PubMed ID: 22289686)

  • 1. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
    Oudard S; Elaidi RT
    Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?
    Calvo E; Ravaud A; Bellmunt J
    Cancer Treat Rev; 2013 Jun; 39(4):366-74. PubMed ID: 22832091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
    Calvo E; Escudier B; Motzer RJ; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Ravaud A; Kim D; Panneerselvam A; Anak O; Figlin RA
    Eur J Cancer; 2012 Feb; 48(3):333-9. PubMed ID: 22209391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
    Patard JJ; Pignot G; Escudier B; Eisen T; Bex A; Sternberg C; Rini B; Roigas J; Choueiri T; Bukowski R; Motzer R; Kirkali Z; Mulders P; Bellmunt J
    Eur Urol; 2011 Oct; 60(4):684-90. PubMed ID: 21704448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
    Grünwald V; Karakiewicz PI; Bavbek SE; Miller K; Machiels JP; Lee SH; Larkin J; Bono P; Rha SY; Castellano D; Blank CU; Knox JJ; Hawkins R; Anak O; Rosamilia M; Booth J; Pirotta N; Bodrogi I;
    Eur J Cancer; 2012 Feb; 48(3):324-32. PubMed ID: 21803569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line therapy for refractory renal-cell carcinoma.
    Zustovich F; Lombardi G; Nicoletto O; Pastorelli D
    Crit Rev Oncol Hematol; 2012 Jul; 83(1):112-22. PubMed ID: 21944739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy.
    Calvo E; Grünwald V; Bellmunt J
    Eur J Cancer; 2014 May; 50(7):1321-9. PubMed ID: 24594299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action.
    Larkin J; Swanton C; Pickering L
    Expert Rev Anticancer Ther; 2011 Apr; 11(4):639-49. PubMed ID: 21504330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-line systemic therapy for the treatment of metastatic renal cell cancer.
    Kruck S; Bedke J; Kuczyk MA; Merseburger AS
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):777-85. PubMed ID: 22716494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study.
    Oudard S; Joly F; Geoffrois L; Laguerre B; Houede N; Barthelemy P; Gross-Goupil M; Vano Y; Lucidarme O; Bidault F; Kelkouli N; Slimane K; Escudier B
    Clin Genitourin Cancer; 2016 Dec; 14(6):e595-e607. PubMed ID: 27283478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.
    Felici A; Bria E; Tortora G; Cognetti F; Milella M
    Expert Rev Anticancer Ther; 2012 Dec; 12(12):1545-57. PubMed ID: 23253221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review.
    Agarwala SS; Case S
    Oncologist; 2010; 15(3):236-45. PubMed ID: 20215359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
    Kapoor A; Figlin RA
    Cancer; 2009 Aug; 115(16):3618-30. PubMed ID: 19479976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Axitinib in metastatic renal cell carcinoma.
    Albiges L; Gizzi M; Carton E; Escudier B
    Expert Rev Anticancer Ther; 2015 May; 15(5):499-507. PubMed ID: 25907705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic therapy in metastatic renal cell carcinoma.
    Bedke J; Gauler T; Grünwald V; Hegele A; Herrmann E; Hinz S; Janssen J; Schmitz S; Schostak M; Tesch H; Zastrow S; Miller K
    World J Urol; 2017 Feb; 35(2):179-188. PubMed ID: 27277600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysis.
    Buchler T; Bortlicek Z; Poprach A; Kubackova K; Kiss I; Zemanova M; Fiala O; Dusek L; Vyzula R; Melichar B;
    Urol Oncol; 2014 Jul; 32(5):569-75. PubMed ID: 24629497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.
    Dranitsaris G; Schmitz S; Broom RJ
    J Cancer Res Clin Oncol; 2013 Nov; 139(11):1917-26. PubMed ID: 24037486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy.
    Vickers MM; Choueiri TK; Rogers M; Percy A; Finch D; Zama I; Cheng T; North S; Knox JJ; Kollmannsberger C; McDermott DF; Rini BI; Heng DY
    Urology; 2010 Aug; 76(2):430-4. PubMed ID: 20223508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.